ICML 2023 | MAIC of pirtobrutinib vs venetoclax in patients with R/R CLL previously treated with a covalent BTKi
In this video, Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the results of a matching-adjusted indirect comparison (MAIC) of pirtobrutinib versus venetoclax continuous monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) previously treated with a covalent BTK inhibitor. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Roche: Education Honorarium, Advisory Board Honorarium, Travel to scientific conferences; Gilead: Honorarium; Research support; Travel to scientific conferences; KITE: Education Honorarium, Advisory Board Honorarium; Janssen: Honorarium; Abbvie: Honorarium; Travel to scientific conferences; AstraZeneca: Honorarium, Research funding, Travel to scientific conferences; Loxo Oncology: Advisory Board Honorarium, Trial steering committee; Beigene: Advisory Board Honorarium, Research funding; Incyte: Advisory Board Honorarium; Secura Bio: Advisory Board Honorarium; Autolus: Advisory Board Honorarium
